Can you take Grepafloxacin with Taron Forte?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- grepafloxacin
- Taron Forte (multivitamin with iron)
Drug interactions
Moderate drug interactions
Moderate:
multivitamins with iron grepafloxacin
Applies to: Taron Forte (multivitamin with iron) and grepafloxacin
Grepafloxacin and multivitamins with iron should not be taken orally at the same time. Products that contain magnesium, aluminum, calcium, iron, and/or other minerals may interfere with the absorption of grepafloxacin into the bloodstream and reduce its effectiveness. If possible, it may be best to avoid taking multivitamins with iron while you are being treated with grepafloxacin. Otherwise, grepafloxacin should be taken 2 to 4 hours before or 4 to 6 hours after a multivitamins with iron dose, grepafloxacin should be taken at least 2 hours before and not less than 6 hours after Suprep Bowel Prep (magnesium/potassium/sodium sulfates), or grepafloxacin and multivitamins with iron should be taken as directed by your healthcare provider. Talk to your healthcare provider if you are unsure whether your medications contain something that could potentially interact or if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
multivitamins with iron Food/Lifestyle
Applies to: Taron Forte (multivitamin with iron)
Food may reduce the absorption and blood levels of multivitamins with iron. In addition, some oral medications can also interfere with multivitamins with iron absorption into the bloodstream, which may make the medication less effective in treating your condition. Likewise, multivitamins with iron may interfere with the absorption of other orally administered medications. You should take multivitamins with iron on an empty stomach at least one hour before or two hours after a meal. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Talk to your doctor or pharmacist if you have questions about how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Rheumatoid Arthritis, Peripheral Neuropathy, Myasthenia Gravis, Organ Transplant, and Renal Dysfunction.
Central Nervous System Disorders
Major:
grepafloxacin
Grepafloxacin has a major potential interaction with Central Nervous System Disorders.
Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures. Benign intracranial hypertension has also been reported. Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities. In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.
Myasthenia Gravis
Major:
grepafloxacin
Grepafloxacin has a major potential interaction with Myasthenia Gravis.
Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis. Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis. Fluoroquinolones should be avoided in patients with history of myasthenia gravis.
Organ Transplant
Major:
grepafloxacin
Grepafloxacin has a major potential interaction with Organ Transplant.
Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment. Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture. Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect. Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.
Peripheral Neuropathy
Major:
grepafloxacin
Grepafloxacin has a major potential interaction with Peripheral Neuropathy.
The use of quinolones has been associated with an increased risk of peripheral neuropathy. Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy. It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.
Renal Dysfunction
Major:
grepafloxacin
Grepafloxacin has a major potential interaction with Renal Dysfunction.
Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment. Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture. Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect. Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.
Rheumatoid Arthritis
Major:
grepafloxacin
Grepafloxacin has a major potential interaction with Rheumatoid Arthritis.
Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment. Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture. Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect. Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.
Report options
More resources
grepafloxacin
A total of 672 drugs are known to interact with grepafloxacin.
- Grepafloxacin is in the drug class quinolones and Fluoroquinolones.
- Grepafloxacin is used to treat Bacterial Infection.
Taron Forte
A total of 106 drugs are known to interact with Taron Forte.
- Taron forte is in the following drug classes: iron products, vitamin and mineral combinations.
- Taron forte is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.